Neil Floch argues GLP-1 receptor agonists have outstanding health benefits but most Americans cannot afford them, framing access as a systemic failure.
It is wonderful that GLP-1ra exist and have outstanding results that cause weightloss, decrease inflammation, and result in improved health.
It is a tragedy that our health system has failed the American public to the point that MOST Americans cannot afford these medications.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare